drugset / Trial / NCT00368069

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

NCT00368069

Phase 3 Completed 158 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.

Timeline

Start
2006-08
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg Oral

Indications